Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1486
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 433–444 of 1,486 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

NCT04916210
Status at this site: Recruiting
View directory record Official record
Conditions
Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting No phase listed Observational

Sleep and Circadian Rhythm Biomarkers of Postoperative Delirium

NCT06052397
Status at this site: Recruiting
View directory record Official record
Conditions
Delirium, Postoperative, Cognitive Decline, Dementia
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
70 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Digital Sleep Optimization for Brain Health Outcomes in Older Surgical Patients

NCT06375265
Status at this site: Recruiting
View directory record Official record
Conditions
Insomnia, Postoperative Delirium, Delayed Neurocognitive Recovery, Postoperative Neurocognitive Disorder
Interventions
digital Cognitive Behavioral Therapy for Insomnia (dCBT-I), Sleep Health Education
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

NCT03149029
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Dabrafenib, Trametinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Effects of Resistance Exercise Among TGD Individuals Initiating Estrogen-Based Gender-Affirming Hormone Therapy

NCT07400419
Status at this site: Recruiting
View directory record Official record
Conditions
Muscle Mass and Strength
Interventions
Resistance Exercise Program, Nutrition and Exercise Counseling
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810
Site status not listed — check the official record
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080
Site status not listed — check the official record
View directory record Official record
Conditions
Large B-Cell Lymphoma
Interventions
Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
60
States / cities
Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting Phase 2 Interventional

Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

NCT07048808
Status at this site: Recruiting
View directory record Official record
Conditions
Refractory Angina, Coronary Artery Disease
Interventions
XC001, Sham (No Treatment)
Combination Product
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

NCT06657222
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
Interventions
TUB-030
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

NCT02134925
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
Interventions
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
Status at this site: Recruiting
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

NCT05077800
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
Interventions
FOLFIRNINOX, Losartan, 9-ING-41
Drug
Lead sponsor
Colin D. Weekes, M.D., PhD
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 4:21 PM EDT

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.